Latest Period
Q4 2025
Security Snapshot
Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) Institutional Ownership
CUSIP: 640979100
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
100
Shares (Excl. Options)
62,936,207
Price
$1.79
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- NMRA on Nasdaq
- Shares outstanding
- 186,788,806
- Price per share
- $1.95
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 62,936,207
- Total reported value
- $112,659,183
- % of total 13F portfolios
- 0%
- Share change
- +12,139,290
- Value change
- +$21,662,425
- Number of holders
- 100
- Price from insider filings
- $1.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NMRA - Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 640979100.
- 100 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 100 to 109 between Q4 2025 and Q1 2026.
- Reported value moved from $112,659,183 to $136,835,153.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 100 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 640979100?
CUSIP 640979100 identifies NMRA - Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 640979100:
Significant Owners of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 19% | -9.5% | $69,289,455 | +$13,162 | 33,965,419 | +0.02% | Kristina Burow | 30 Mar 2026 |
| Invus Global Management, LLC | 4.7% | -14% | $16,570,753 | -$975,000 | 8,497,822 | -5.6% | Raymond Debbane | 31 Mar 2026 |
| BERNS PAUL L | 5.1% | $6,334,229 | 8,226,272 | Paul L Berns | 31 Dec 2024 | |||
| K2 HealthVentures Equity Trust LLC | 3.1% | -38% | $11,291,383 | -$6,252,835 | 5,790,453 | -36% | K2 HealthVentures Equity Trust LLC | 31 Mar 2026 |
| FMR LLC | 2.2% | $2,692,163 | 3,496,316 | FMR LLC | 31 Mar 2025 |
As of 31 Dec 2025, 100 institutional investors reported holding 62,936,207 shares of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA). This represents 34% of the company’s total 186,788,806 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) together control 30% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SOFTBANK GROUP CORP. | 3.4% | 6,429,720 | -1.7% | 0.07% | $11,509,199 |
| Siren, L.L.C. | 3.4% | 6,288,783 | +44% | 0.34% | $11,256,922 |
| VANGUARD GROUP INC | 2.4% | 4,539,261 | +12% | 0% | $8,125,277 |
| MIC Capital Management UK LLP | 2.4% | 4,460,700 | 0% | 1.8% | $7,984,654 |
| Point72 Asset Management, L.P. | 2% | 3,673,839 | 0.01% | $6,576,172 | |
| MILLENNIUM MANAGEMENT LLC | 1.9% | 3,616,514 | +80% | 0% | $6,473,560 |
| FMR LLC | 1.9% | 3,498,269 | -0.1% | 0% | $6,261,902 |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 1.8% | 3,309,123 | 0% | 0.06% | $5,923,330 |
| ICONIQ Capital, LLC | 1.4% | 2,559,090 | 0% | 0.07% | $4,580,771 |
| Lunate Capital Ltd | 1.1% | 2,124,143 | 0% | 1.4% | $3,802,216 |
| BlackRock, Inc. | 1.1% | 2,024,944 | +12% | 0% | $3,624,649 |
| JOHNSON & JOHNSON | 0.99% | 1,849,445 | 0% | 0.6% | $3,310,507 |
| RENAISSANCE TECHNOLOGIES LLC | 0.77% | 1,445,902 | +24% | 0% | $2,588,165 |
| TWO SIGMA INVESTMENTS, LP | 0.7% | 1,307,688 | +336% | 0% | $2,340,762 |
| Ikarian Capital, LLC | 0.68% | 1,278,408 | +10129% | 0.3% | $2,288,351 |
| JANE STREET GROUP, LLC | 0.6% | 1,128,972 | +624% | 0% | $2,020,860 |
| TWO SIGMA ADVISERS, LP | 0.58% | 1,083,400 | +11% | 0% | $1,939,286 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.54% | 1,003,746 | +3.6% | 0% | $1,797,457 |
| TANG CAPITAL MANAGEMENT LLC | 0.52% | 967,235 | -31% | 0.09% | $1,731,351 |
| GOLDMAN SACHS GROUP INC | 0.46% | 858,502 | +127% | 0% | $1,536,719 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.4% | 738,272 | +74% | 0% | $1,321,507 |
| AlphaCore Capital LLC | 0.34% | 638,784 | 0% | 0.03% | $1,143,423 |
| MARSHALL WACE, LLP | 0.31% | 583,758 | 0% | $1,044,927 | |
| GSA CAPITAL PARTNERS LLP | 0.29% | 534,044 | +393% | 0.08% | $956,000 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.27% | 512,470 | -0.09% | 0% | $917,321 |
Institutional Holders of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 70,178,607 | $136,835,153 | +$14,416,144 | $1.95 | 109 |
| 2025 Q4 | 62,936,207 | $112,659,183 | +$21,662,425 | $1.79 | 100 |
| 2025 Q3 | 50,688,208 | $92,241,263 | -$7,574,740 | $1.82 | 91 |
| 2025 Q2 | 56,105,109 | $41,177,547 | -$6,520,439 | $0.73 | 96 |
| 2025 Q1 | 65,233,736 | $65,235,367 | -$163,396,114 | $1.00 | 111 |
| 2024 Q4 | 80,333,766 | $851,575,296 | +$93,329,557 | $10.60 | 132 |
| 2024 Q3 | 68,678,182 | $907,013,068 | +$21,361,695 | $13.21 | 103 |
| 2024 Q2 | 63,827,298 | $627,414,966 | +$100,142,866 | $9.83 | 92 |
| 2024 Q1 | 52,696,596 | $725,374,900 | +$114,726,209 | $13.75 | 86 |
| 2023 Q4 | 43,747,888 | $744,815,306 | +$130,275,365 | $17.05 | 60 |
| 2023 Q3 | 36,353,167 | $512,042,809 | +$512,042,809 | $14.11 | 38 |